libre de droit
Corbus Pharmaceuticals (NASDAQ:CRBP) said that its antibody drug conjugate, CRB-701, demonstrated promising efficacy and safety data in a phase 1 trial.
Patients in the study, which took place in China, had Nectin-4 positive urothelial or cervical cancer, and had failed or were intolerant to standard treatment. Urothelial cancer is the most common type of bladder cancer.
Data was presented from across seven doses and two PK cohorts.
Results showed that to date, in urothelial cancer, the overall response rate (ORR) as 44% and disease control rate (DCR) was 78%. For patients with cervical cancer, the results were, respectively, 43% and 86%.
All tumor types at doses ≥ 2.7 mg/Kg resulted in 40% ORR and 73% DCR.
Corbus noted that CRB-701 was generally well tolerated with mainly grade 1 or 2 adverse events, with no dose-limiting toxicities or grade 4 or 5 events seen to date. Anemia and eye-related treatment emergent adverse events were the most common ones reported.
However, two grade 3 corneal disorders were reported in patients who received 2.7 mg/Kg and 3.6 mg/Kg doses.
CRB-701 could potentially compete against Pfizer-owned (PFE) Seagen and Astellas Pharma’s (OTCPK:ALPMF)(OTCPK:ALPMY) Padcev (enfortumab vedotin), another Nectin-4-directed ADC. In May, an RBC Capital Markets report cited CRB-701’s longer half-life, more potent cell killing, and improved side effect profile as potential advantages over Padcev.
